Haleon PLC
Company Profile
Business description
Haleon is one of the largest consumer health companies in the world. Formed by a combination of consumer health divisions of GSK, Pfizer, and Novartis, Haleon separated from GSK and went public in July 2022. The firm generates 60% of sales from global power brands including Sensodyne, Advil, Centrum, and Poligrip, that play in many geographies and are often leaders in their respective categories. It also has a number of local brands, including Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity. Overall, Haleon’s brands tackle a variety of silos within consumer health including oral care, digestive health, pain relief, and nutrition.
Contact
The Heights
Building 5, First Floor
WeybridgeSurreyKT13 0NY
GBRT: +44 1932959500
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
24,524
Stocks News & Analysis
stocks
Undervalued ASX share retains wide moat rating despite regulatory pressures
stocks
Our top ASX picks in every sector
stocks
Tesla: Shares fall as deliveries come in below consensus
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.70 | 2.00 | 0.02% |
| CAC 40 | 8,297.27 | 388.53 | 4.91% |
| DAX 40 | 24,086.19 | 1,164.60 | 5.08% |
| Dow JONES (US) | 47,916.37 | 1,331.91 | 2.86% |
| FTSE 100 | 10,658.69 | 309.90 | 2.99% |
| HKSE | 25,893.02 | 776.49 | 3.09% |
| NASDAQ | 22,643.98 | 626.13 | 2.84% |
| Nikkei 225 | 56,308.42 | 2,878.86 | 5.39% |
| NZX 50 Index | 13,253.94 | 184.28 | 1.41% |
| S&P 500 | 6,774.58 | 157.73 | 2.38% |
| S&P/ASX 200 | 8,951.80 | 21.00 | -0.23% |
| SSE Composite Index | 3,995.00 | 104.83 | 2.69% |